Iyer, Lavanya M.

[["dc.bibliographiccitation.firstpage","288"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.lastpage","298"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Horwitz, S."],["dc.contributor.author","O'Connor, O.A."],["dc.contributor.author","Pro, B."],["dc.contributor.author","Trümper, L."],["dc.contributor.author","Iyer, S."],["dc.contributor.author","Advani, R."],["dc.contributor.author","Bartlett, N.L."],["dc.contributor.author","Christensen, J.H."],["dc.contributor.author","Morschhauser, F."],["dc.contributor.author","Domingo-Domenech, E."],["dc.contributor.author","Illidge, T."],["dc.date.accessioned","2022-04-01T10:01:00Z"],["dc.date.available","2022-04-01T10:01:00Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1016/j.annonc.2021.12.002"],["dc.identifier.pii","S0923753421048754"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105575"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.issn","0923-7534"],["dc.rights.uri","https://www.elsevier.com/tdm/userlicense/1.0/"],["dc.title","The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]